SCHEMBL12436950

SCHEMBL12436950

CC(=O)C1CCN(C(=O)C2CC(F)(F)C2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.40
CASP3 P42574 1/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
TSHR P16473 2/20 0.38
EPHX2 P34913 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
LMNA P02545 2/20 0.36
MAPK1 P28482 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA4 P43681 1/20 0.36
CHRNB3 Q05901 1/20 0.36
CHRNA6 Q15825 1/20 0.36
AOC2 O75106 1/20 0.36
TACR3 P29371 1/20 0.36
HRH3 Q9Y5N1 3/20 0.36
RECQL P46063 1/20 0.36
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12436924 0.84 EPHX2 (0.46) SMN1; SMN2CASP3ALDH1A1HPGDTSHR
SCHEMBL20981022 0.84 MAPT (0.42) SMN1; SMN2CASP3ALDH1A1HPGDTSHR
SCHEMBL17546307 0.84 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1HPGDTSHRMEN1
SCHEMBL30333499 0.83 TSHR (0.42) SMN1; SMN2CASP3ALDH1A1HPGDTSHR
SCHEMBL19249293 0.81 CASP3 (0.38) SMN1; SMN2CASP3ALDH1A1HPGDTSHR
SCHEMBL12436922 0.81 HPGD (0.58) SMN1; SMN2ALDH1A1HPGDTSHRMEN1
SCHEMBL12437062 0.79 HPGD (0.47) SMN1; SMN2ALDH1A1HPGDTSHREPHX2
SCHEMBL12513662 0.79 HPGD (0.47) SMN1; SMN2ALDH1A1HPGDTSHREPHX2
SCHEMBL20981026 0.78 ALDH1A1 (0.67) ALDH1A1TSHRMEN1KMT2A
SCHEMBL22549555 0.77 ALDH1A1 (0.65) SMN1; SMN2ALDH1A1HPGDTSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE48334-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-12-01 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
EP-2336105-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME Takeda Pharmaceutical Company Limited (JP) 2011-06-22 EP disclosed
WO-2010032856-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME 武田薬品工業株式会社 (JP) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME NTSR2, BDKRB1, AVPR1B SMN1; SMN2 1248/4885CASP3 3721/4885ALDH1A1 3648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.